Drug-related psoriasis
Authors:
Open Access
- 1 January 2023
- journal article
- letter
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 40 (3) , 470-471
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021JAAD International, 2022
- Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic reviewRheumatology, 2022
- A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidenceScientific Reports, 2021
- Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of PsoriasisJAMA Dermatology, 2021
- The role of xenobiotics in triggering psoriasisArchives of Toxicology, 2020
- Systemic corticosteroid use in psoriasis: a national survey of board‐certified dermatologistsJournal of the European Academy of Dermatology and Venereology, 2018
- Drug-induced psoriasis: clinical perspectivesPsoriasis: Targets and Therapy, 2017
- Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?Journal of the European Academy of Dermatology and Venereology, 2012
- Drug-Induced Psoriasis: An Evidence-Based Overview and the Introduction of Psoriatic Drug Eruption Probability ScoreCutaneous and Ocular Toxicology, 2006
- Drug-Induced PsoriasisAmerican Journal of Clinical Dermatology, 2000